In Q32021, ISR asked new & emerging biopharma respondents (those with R&D <$500M) which CDMOs they are currently working with, and if the choice were entirely up to them, which CDMO would they prefer to use for all biologic drug substance manufacturing. The data show Catalent and Lonza are the preferred CDMO among nearly roughly of their new & emerging biopharma users. Patheon follows, as the preferred CDMO among one-third of new & emerging biopharma users included in the survey. This poses a threat to smaller CDMOs that want to win virtual biopharma business and is a sign that the CDMO giants are effectively adapting the the needs of this customer group. To learn more about CDMO preference among users, follow the link to the Biologic API CDMO Benchmarking report preview.